Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women (Q34589830)

3 August 2017

title

Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women (English)

1 reference

3 August 2017

1 reference

13

Erica Villa

1 reference

3 August 2017

Laura Turco

5

0 references

Salvatore Petta

object named as

Salvatore Petta

3

0 references

Caterina Sagnelli

object named as

Caterina Sagnelli

10

0 references

Mario Rizzetto

11

object named as

Mario Rizzetto

1 reference

3 August 2017

Veronica Bernabucci

1

1 reference

3 August 2017

Alessia Ciancio

2

1 reference

3 August 2017

Aimilia Karampatou

4

1 reference

3 August 2017

Silvia Strona

6

1 reference

3 August 2017

Rosina Critelli

7

1 reference

3 August 2017

Paola Todesca

8

1 reference

3 August 2017

Caterina Cerami

9

1 reference

3 August 2017

Calogero Cammà

12

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 November 2014

1 reference

World Journal of Gastroenterology

3 August 2017

published in

1 reference

3 August 2017

volume

20

1 reference

3 August 2017

issue

44

1 reference

3 August 2017

page(s)

16726-16733

1 reference

Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Reproductive status is associated with the severity of fibrosis in women with hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Genomics and HCV infection: progression of fibrosis and treatment response

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Boceprevir for previously treated chronic HCV genotype 1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Boceprevir for untreated chronic HCV genotype 1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Chronic hepatitis C and fibrosis: evidences for possible estrogen benefits

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Risk factors for liver fibrosis progression in patients with chronic hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Changes in proinflammatory cytokine activity after menopause

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response

7 July 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I44.16726

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I44.16726

Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I44.16726

Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I44.16726

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I44.16726

Factors that predict response of patients with hepatitis C virus infection to boceprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I44.16726

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248219

10.3748/WJG.V20.I44.16726

27 October 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

3 August 2017

1 reference